Non-profit agency Solve M.E. disclosed on Thursday that Rep. Don Beyer and Rep. Jack Bergmanhave introduced the historic COVID-19 Long Haulers Act (H.R. 2754) bipartisan legislation to authorise the funding of research of up to USD100m for COVID-19 patients.
Solve M.E. and the Long COVID Alliance worked closely with Representative Beyer's office to help craft data-driven policy solutions that meet the diverse needs of ALL long haulers and post-infectious illness patients. While 2.5m Americans currently suffer from Myalgic Encephalomyelitis, Chronic Fatigue Syndrome (ME/CFS) and Long COVID, the experts estimate two-fold growth as a result of COVID-19.
The COVID-19 Long Haulers Act was introduced following the 5th Annual ME/CFS Advocacy Week hosted by the Solve M.E. The three members of Congress and a record number of participants held nearly 350 congressional meetings--pushing for more funding and support.
Under the COVID-19 Long Haulers Act (H.R. 2754), about USD30m is for the Patient-Centered Outcomes Research Institute (PCORI), USD33m for Healthcare Research and Quality (AHRQ) and Centers for Medicare & Medicaid Services (CMS) as well as USD30m for the Centers for Disease Control and Prevention (CDC) to develop and disseminate information for medical providers and the general public.
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy